BR9305674A - Nabumetone endurecido por spray - Google Patents

Nabumetone endurecido por spray

Info

Publication number
BR9305674A
BR9305674A BR9305674-5A BR9305674A BR9305674A BR 9305674 A BR9305674 A BR 9305674A BR 9305674 A BR9305674 A BR 9305674A BR 9305674 A BR9305674 A BR 9305674A
Authority
BR
Brazil
Prior art keywords
pct
nabumetone
spray
sec
hardened
Prior art date
Application number
BR9305674-5A
Other languages
English (en)
Inventor
Graham Stanley Leonard
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR9305674A publication Critical patent/BR9305674A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coating By Spraying Or Casting (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Freezing, Cooling And Drying Of Foods (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Road Signs Or Road Markings (AREA)
  • Catching Or Destruction (AREA)

Abstract

"NABUMETONE ENDURECIDO POR SPRAY". Trata-se de nabumetone que é endurecido por spray na forma de dose unitária com volume menor do que os já existentes facilitando a ingestão.
BR9305674-5A 1992-01-29 1993-01-22 Nabumetone endurecido por spray BR9305674A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929201857A GB9201857D0 (en) 1992-01-29 1992-01-29 Novel compound
PCT/GB1993/000145 WO1993014747A1 (en) 1992-01-29 1993-01-22 Spray-chilled nabumetone

Publications (1)

Publication Number Publication Date
BR9305674A true BR9305674A (pt) 2005-01-11

Family

ID=10709436

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9305674-5A BR9305674A (pt) 1992-01-29 1993-01-22 Nabumetone endurecido por spray

Country Status (24)

Country Link
US (1) US5539000A (pt)
EP (1) EP0624087B1 (pt)
JP (1) JPH07503245A (pt)
KR (1) KR950700056A (pt)
CN (1) CN1079954A (pt)
AT (1) ATE150298T1 (pt)
AU (1) AU3362693A (pt)
BG (1) BG98933A (pt)
BR (1) BR9305674A (pt)
CA (1) CA2129027A1 (pt)
CZ (1) CZ182894A3 (pt)
DE (1) DE69309037T2 (pt)
DK (1) DK0624087T3 (pt)
ES (1) ES2099419T3 (pt)
FI (1) FI943550A0 (pt)
GB (1) GB9201857D0 (pt)
GR (1) GR3023142T3 (pt)
HU (1) HUT67462A (pt)
IL (1) IL104526A0 (pt)
MX (1) MX9300430A (pt)
NO (1) NO942813L (pt)
SK (1) SK91694A3 (pt)
WO (1) WO1993014747A1 (pt)
ZA (1) ZA93577B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9920148D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel composition
TWI262791B (en) 1999-10-27 2006-10-01 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
US6552078B2 (en) 1999-10-27 2003-04-22 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
US20020132010A1 (en) * 2000-12-22 2002-09-19 Yihong Qui Divalproex sodium dosage forms and a process for their production
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20060083791A1 (en) * 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
BRPI0417338A (pt) * 2003-12-04 2007-04-17 Pfizer Prod Inc formas de dosagem de azitromicina multiparticulada por processos a base de lìquido
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
CA2547597A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
JP2007513147A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
SI1691787T1 (sl) * 2003-12-04 2008-10-31 Pfizer Prod Inc Postopek za pripravo farmacevtskih produktov iz več delcev
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
BRPI0416535A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc processo de congelamento por vaporização empregando um extrusor para preparar composições de azitromicina de multiparticulado contendo preferivelmente um poloxámero e um glicerìdeo
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
EP1809305A4 (en) * 2004-10-15 2009-12-30 Altairnano Inc PHOSPHATE BINDER WITH REDUCED TABLET LOAD
AU2006279343A1 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) * 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
CA3224506A1 (en) 2010-05-12 2011-11-17 Unicycive Therapeutics, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
EP3544614A4 (en) 2016-11-28 2020-08-05 Lipocine Inc. ORAL TESTOSTERONE UNDECANOATE THERAPY

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4420639C1 (en) * 1973-09-11 2001-08-21 Beecham Group Ltd Aromatic compounds
GB1474377A (en) 1973-09-11 1977-05-25 Beecham Group Ltd Naphthalene derivatives
US4086346A (en) * 1974-04-06 1978-04-25 Bayer Aktiengesellschaft Preparation of melt-sprayed spherical phenacetin granules
DE3833446A1 (de) 1988-10-01 1990-04-05 Hoechst Ag Verfahren zur herstellung von arzneimittelwirkstoff-partikeln mit verbesserten fliess-, lager- und formulierungseigenschaften sowie arzneimittel, die diese arzneimittelwirkstoff-partikeln enthalten

Also Published As

Publication number Publication date
FI943550A (fi) 1994-07-28
CZ182894A3 (en) 1995-02-15
DE69309037T2 (de) 1997-07-24
FI943550A0 (fi) 1994-07-28
BG98933A (en) 1995-07-28
CA2129027A1 (en) 1993-08-05
NO942813D0 (no) 1994-07-28
GR3023142T3 (en) 1997-07-30
ATE150298T1 (de) 1997-04-15
ES2099419T3 (es) 1997-05-16
NO942813L (no) 1994-07-28
AU3362693A (en) 1993-09-01
IL104526A0 (en) 1993-05-13
SK91694A3 (en) 1995-03-08
EP0624087A1 (en) 1994-11-17
KR950700056A (ko) 1995-01-16
CN1079954A (zh) 1993-12-29
JPH07503245A (ja) 1995-04-06
EP0624087B1 (en) 1997-03-19
DK0624087T3 (da) 1997-09-01
ZA93577B (en) 1994-01-13
WO1993014747A1 (en) 1993-08-05
DE69309037D1 (de) 1997-04-24
GB9201857D0 (en) 1992-03-18
US5539000A (en) 1996-07-23
HUT67462A (en) 1995-04-28
MX9300430A (es) 1994-08-31
HU9402221D0 (en) 1994-09-28

Similar Documents

Publication Publication Date Title
BR9305674A (pt) Nabumetone endurecido por spray
FR2656928B1 (fr) Dispositif ameliore d'immunotest du type plaquette a plonger, et trousse contenant ce dispositif.
FI953091A (fi) Virtsasta peräisin oleva uusi proteiini, jota kutsutaan komponentti B:ksi
FR2693112B1 (fr) Dispositif électromécanique d'injection à usage médical et vétérinaire actionné par une gâchette.
FR2713889B1 (fr) Composition pesticide contenant un régulateur de la croissance des insectes et un dérivé de N-aryldiazole.
ES2136910T3 (es) Solucion de interferon.
IS5265A (is) Sertralín sölt og viðhalds-losandi skammtaform afsertralíni
FR2676173B1 (fr) Composition cosmetique contenant un agent alcalinisant sans odeur.
IT8121735A0 (it) Sorgente di polverizzazione intensificata magneticamente.
DE59300287D1 (de) Verbesserte entsorgung von kontaminiertem bohrklein.
SE9002468D0 (sv) A device and method for dosing a liquid product
FR2692883B1 (fr) Verres thermiquement stables et chimiquement résistants.
ES2131528T3 (es) Nuevos polipeptidos y su uso.
DE69324718D1 (de) Thermisch abhängige, selbständernde Spannungsquelle
DE59006159D1 (de) Verwendung von macrolactonen als antiallergica.
EP0828493A4 (en) 4.4-DISUBSTITUTED CYCLOHEXANE-1-OL MONOMERS AND RELATED COMPOUNDS
ES2122005T3 (es) Medicamento que contiene (-)-metrifonato.
ES2145125T3 (es) Disposicion de proteccion de conmutador.
ZA939199B (en) Methylbutoxy-propionitriles
ES1019098Y (es) Camara de aireacion y amortizacion para calzados.
TW366338B (en) Arylalkoxyphenoxy-imidazoline compounds
FR2668993B1 (fr) Dispositif d'actionnement d'un maitre cylindre.
KR940010354U (ko) 클러치 부스터(clutch booster)
FR2692483B1 (fr) Masques dermiques énergétiques.
ITMO910013U1 (it) Emanatore di profumo di essenze, ricaricabile, per deodorare e profuma re ambienti.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]